After hitting a regulatory roadblock in 2022, Sanofi’s consumer healthcare business Opella has secured the FDA’s blessing to ...

Sanofi’s (NASDAQ:SNY) consumer healthcare unit Opella announced Tuesday that the U.S. FDA has lifted a clinical hold on a ...

The FDA has warned Sanofi about a series of “significant” manufacturing problems, including contamination, at a key facility ...

French pharmaceutical giant Sanofi has received a warning letter from the U.S. Food and Drug Administration following an ...

Sanofi’s divestment continues a trend among pharma companies to divest their consumer health divisions to focus on prescription drugs, recognising that consumer health products require different ...

French pharma major Sanofi’s consumer healthcare business, Opella, has announced that the US Food and Drug Administration ...

Sanofi (SNYNF – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Graham Parry from Bank ...

Sanofi’s SNY stock has declined 10.2% in the past three months. However, a lot of this price decline was due to the downtrend of the overall drug and biotech sector, which performed poorly in the past ...

Clarius Group LLC lifted its holdings in shares of Sanofi (NASDAQ:SNY – Free Report) by 11.9% in the fourth quarter, ...

Sanofi’s Dupixent and new drugs drive growth, despite near-term pressures. See why SFY stock’s product pipeline makes it a ...

J.P. Morgan analyst Richard Vosser maintained a Hold rating on Sanofi (SNYNF – Research Report) today and set a price target of €105.00. The ...